Ascendis Pharma

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ASND and other ETFs, options, and stocks.

About ASND

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes on its TransCon technologies to create prodrugs that provide for the predictable and sustained release of an unmodified parent drug. 

CEO
Jan Møller Mikkelsen
CEOJan Møller Mikkelsen
Employees
Employees
Headquarters
Hellerup, Capital Region
HeadquartersHellerup, Capital Region
Founded
2006
Founded2006
Employees
Employees

ASND Key Statistics

Market cap
6.86B
Market cap6.86B
Price-Earnings ratio
-13.08
Price-Earnings ratio-13.08
Dividend yield
Dividend yield
Average volume
552.55K
Average volume552.55K
High today
$123.99
High today$123.99
Low today
$120.02
Low today$120.02
Open price
$123.06
Open price$123.06
Volume
640.83K
Volume640.83K
52 Week high
$161.00
52 Week high$161.00
52 Week low
$83.75
52 Week low$83.75

ASND News

TipRanks 3d
Ascendis Pharma Expands Capital with Warrants and Shares - TipRanks.com - TipRanks

Ascendis Pharma A/S (ASND) has released an update. Ascendis Pharma A/S, a company focused on developing medical treatments for diseases, has announced changes...

TipRanks 4d
Ascendis says TransCon PTH PDUFA target action date extended three months - TipRanks.com - TipRanks

Ascendis Pharma announced that the U.S. Food and Drug Administration notified the company that information submitted in response to the FDA’s ongoing review of...

Benzinga 5d
FDA Pushes Review Date For Ascendis Pharma's Hormone Disorder Candidate By Three Months - Ascendis Pharma - Benzinga

Loading... Loading... Tuesday, Ascendis Pharma A/S ASND announced that the FDA extended the review date for TransCon PTH (palopegteriparatide) for adults with...

FDA Pushes Review Date For Ascendis Pharma's Hormone Disorder Candidate By Three Months - Ascendis Pharma - Benzinga

Analyst ratings

77%

of 13 ratings
Buy
76.9%
Hold
23.1%
Sell
0%

More ASND News

Seeking Alpha 5d
Ascendis Pharma says FDA has delayed TransCon PTH review

Ascendis Pharma (ASND) announced Tuesday that the U.S. Food and Drug Administration (FDA) has pushed back the timeline to complete its review of the company's i...

Ascendis Pharma says FDA has delayed TransCon PTH review
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.